OptiNose (NASDAQ:OPTN – Get Free Report) and ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.
Valuation and Earnings
This table compares OptiNose and ProQR Therapeutics’ revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
OptiNose | $75.06 million | 1.40 | -$35.48 million | ($0.27) | -3.44 |
ProQR Therapeutics | $15.41 million | 11.09 | -$30.43 million | ($0.37) | -5.68 |
ProQR Therapeutics has lower revenue, but higher earnings than OptiNose. ProQR Therapeutics is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
Analyst Recommendations
This is a summary of current ratings for OptiNose and ProQR Therapeutics, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
OptiNose | 0 | 0 | 2 | 0 | 3.00 |
ProQR Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
OptiNose currently has a consensus target price of $4.00, suggesting a potential upside of 330.11%. ProQR Therapeutics has a consensus target price of $3.38, suggesting a potential upside of 60.71%. Given OptiNose’s higher possible upside, equities analysts plainly believe OptiNose is more favorable than ProQR Therapeutics.
Profitability
This table compares OptiNose and ProQR Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
OptiNose | -54.50% | N/A | -38.53% |
ProQR Therapeutics | -140.17% | -55.42% | -16.50% |
Risk & Volatility
OptiNose has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.
Summary
OptiNose beats ProQR Therapeutics on 7 of the 13 factors compared between the two stocks.
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.